Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report

BMC Cancer

Case Report

Hou-Tai Chang¹  Yen-Ping Hsieh²  Ngot-Swan Chong³  Chien-An Chen³  Pei-Wei Shueng⁴  Chen-Hsi Hsieh⁵  Shoei Long Lin⁶  Shih-Chiang Lin⁷  Chun-Yi Chen⁸  Yu-Jen Chen⁹  Li-Ying Wang^1,10 

[1] Department of Chest Medicine, Division of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan;Department of Healthcare Administration, Asia University, Taichung, Taiwan;Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan;Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan;Department of Radiation Oncology, National Defense Medical Center, Taipei, Taiwan;Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan;Institutes of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan;Department of Surgery, Department of Health, Taipei Hospital, Taipei, Taiwan;Department of hematology, Far Eastern Memorial Hospital, Taipei, Taiwan;Division of Medical Oncology, Department of Internal Medicine, Department of Health, Taipei Hospital, Taipei, Taiwan;Institutes of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan;Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan;School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan;

关键词: Epidermal Growth Factor Receptor;    Erlotinib;    Interstitial Lung Disease;    NSCLC Patient;    Stereotactic Body Radiation Therapy;   

DOI  :  10.1186/1471-2407-10-696

 received in 2010-06-02, accepted in 2010-12-31,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundStereotactic body radiation therapy (SBRT) applied by helical tomotherapy (HT) is feasible for lung cancer in clinical. Using SBRT concurrently with erlotinib for non-small cell lung cancer (NSCLC) is not reported previously.Case PresentationA 77-year-old man with stage III NSCLC, received erlotinib 150 mg/day, combined with image-guided SBRT via HT. A total tumor dose of 54 Gy/9 fractions was delivered to the tumor bed. The tumor responded dramatically and the combined regimen was well tolerated. After concurrent erlotinib-SBRT, erlotinib was continued as maintenance therapy. The patient developed dyspnea three months after the combined therapy and radiation pneumonitis with interstitial lung disease was suspected.ConclusionsCombination SBRT, HT, and erlotinib therapy provided effective anti-tumor results. Nonetheless, the potential risks of enhanced adverse effects between radiation and erlotinib should be monitored closely, especially when SBRT is part of the regimen.

【 授权许可】

CC BY   
© Hsieh et al; licensee BioMed Central Ltd. 2010